Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating
Source: Dr. Joseph Pantginis  (9/23/22)
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report. More >

Analyst Says Buy Before Biotech Co.'s Clinical Trials
Source: Dr. David Nierengarten  (9/23/22)
Argenx SE has "several upcoming catalysts," noted a Wedbush report. More >

FDA Approves Hearing Loss Drug for Child Chemo Patients
Source: Streetwise Reports  (9/21/22)
Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors. More >

Dermatology Co.'s Target Price Much Higher Than Current
Source: Dr. Jonathan Aschoff  (9/20/22)
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report. More >

Important Catalyst Expected Soon for Cancer Drug Co.
Source: Dr. David Nierengarten  (9/20/22)
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report. More >

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data
Source: Streetwise Reports  (9/20/22)
Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23. More >

Second Trial of New Eczema Drug To Commence in Q4/22
Source: Dr. Yi Chen  (9/17/22)
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report. More >

FDA Grants Approval for Drug Improving Kidney Function
Source: Streetwise Reports  (9/16/22)
Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function. More >

Price Target on US Biopharma Co. Boosted by $15
Source: Julian Harrison  (9/15/22)
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report. More >

New Drug Shown To Help Patients With Desmoid Tumors
Source: Dr. David Nierengarten  (9/15/22)
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report. More >

NDA for Dry Eye Disease Drug on Track for Q4/22 Submission
Source: Justin Kim   (9/15/22)
This and the biopharma's other treatment candidates for ocular diseases are underappreciated, which translates to an investment opportunity, noted an Oppenheimer report. More >

Co. Advancing Drug Class With Broad Potential
Source: Dr. Thomas Shrader   (9/13/22)
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report. More >

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'
Source: Clive Maund  (9/13/22)
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive. More >

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet
Source: Streetwise Reports  (9/12/22)
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run. More >

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise
Source: Dr. Jonathan Aschoff  (9/12/22)
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report. More >

US Co. To Regain All Rights to Its AGHD Diagnostic Test
Source: Dr. Ram Selvaraju  (9/8/22)
This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report. More >

Medtech Co. Meets Primary Endpoints in Ph. 3 Glaucoma Trials
Source: Streetwise Reports  (9/8/22)
Glaukos Corp.'s shares traded 18% higher yesterday after the company reported that in two separate Phase 3 trials, its iDose TR met its primary efficacy endpoints by lowering intraocular pressure in glaucoma patients. More >

Biopharma Co. Receives Approval From FDA Panel for ALS Drug
Source: Streetwise Reports  (9/8/22)
Amylyx Pharmaceuticals Inc.'s shares traded 51% higher after the company reported that a U.S. FDA advisory committee has voted to support approval of the firm's AMX0035 for use in treating amyotrophic lateral sclerosis. Although the committee's recommendation is not binding, it is expected that the decision will provide staunch support for approval of the firm's pending NDA for AMX0035, which has a target action date of September 29, 2022. More >

Biopharma Co. Transforming Injected Drugs Into Pills
Source: Dr. Ram Selvaraju  (9/7/22)
This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it. More >

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling
Source: Clive Maund  (9/7/22)
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen. More >

Two Talks On New Cancer Drug Slated for Meeting This Week
Source: Dr. Tony Butler  (9/6/22)
The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report. More >

Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?
Source: Streetwise Reports  (9/4/22)
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August. More >

Denmark Co. To Buy US Biopharma Co. for $1.1 Billion
Source: Streetwise Reports  (9/2/22)
Forma Therapeutics Holdings Inc. shares traded 51% higher yesterday after the company reported it agreed to be acquired by Denmark's Novo Nordisk A/S in an all-cash deal for $20.00 per share. With the acquisition, Novo Nordisk aims to expand its global presence in the treatment of rare blood disorders and sickle cell disease. More >

Expert Rates Pharma Co. An Immediate Buy
Source: Chris Temple  (9/1/22)
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough. More >

FDA OKs Biopharma to Trial New Cell Therapy
Source: Mitchell Kapoor  (8/30/22)
Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report. More >